| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Insider buying and selling activity across 114 companies in the Pharmaceuticals industry. Part of the Health Care sector.
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Oct 4, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 116,038 | $112.67 | $13,073,950.24 | - | |
| Oct 3, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 78,962 | $109.01 | $8,607,252.81 | - | |
| Oct 3, 2018 | BCRX Biocryst Pharmaceuticals Inc | Staab Thomas R II | Senior Vice President And CFO | Sell | 9,850 | $7.24 | $71,357.78 | -1.8% | |
| Oct 2, 2018 | MRK Merck & Co., Inc. | Frazier Kenneth C | Chairman, President &CEO | Sell | 279,850 | $72.07 | $20,168,257.79 | -28.8% | |
| Oct 1, 2018 | ALKS Alkermes Plc. | Mitchell Paul J | Director | Sell | 1,000 | $42.42 | $42,420.00 | -100% | |
| Oct 1, 2018 | MRK Merck & Co., Inc. | Merck & Co., Inc. | 10% Owner | Buy | 666,666 | $15.00 | $9,999,990.00 | +32.4% | |
| Oct 1, 2018 | AMRN Amarin Corp Plc\uk | Kennedy Joseph T | General Counsel | Sell | 50,249 | $16.81 | $844,528.35 | -6.9% | |
| Oct 1, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 316,604 | $16.13 | $5,105,588.80 | -22.0% | |
| Sep 28, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 107,553 | $107.31 | $11,541,082.22 | - | |
| Sep 28, 2018 | AZN Astrazeneca Plc | Astrazeneca Plc | 10% Owner | Buy | 246,666 | $15.00 | $3,699,990.00 | +12.9% | |
| Sep 28, 2018 | TXMD Therapeuticsmd, Inc. | Bernick Brian | Director | Sell | 182,800 | $6.59 | $1,204,560.60 | -1.4% | |
| Sep 27, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 92,447 | $107.00 | $9,891,644.11 | - | |
| Sep 26, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 134,410 | $106.63 | $14,332,372.84 | - | |
| Sep 26, 2018 | TXMD Therapeuticsmd, Inc. | Milligan John C.K. IV | President/ Secretary | Sell | 250,000 | $6.78 | $1,694,250.00 | -7.8% | |
| Sep 25, 2018 | LLY Eli Lilly & Co | Lilly Endowment Inc | 10% Owner | Sell | 55,590 | $106.41 | $5,915,165.13 | - | |
| Sep 25, 2018 | AMRN Amarin Corp Plc\uk | Ketchum Steven B | Chief Scientific Officer | Sell | 879,241 | $11.10 | $9,760,023.88 | -30.0% | |
| Sep 24, 2018 | LLY Eli Lilly & Co | Lilly Eli & Co | 10% Owner | Sell | 2,027 | $16.36 | $33,161.72 | - | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Urbanek David Alan | See Remarks | Buy | 500 | $24.00 | $12,000.00 | New | |
| Sep 24, 2018 | TLPH Talphera, Inc. | Hamel Lawrence G | Chief Development Officer | Sell | 6,953 | $4.50 | $31,288.50 | -16.6% | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Meer James M | Chief Accounting Officer | Buy | 225 | $24.00 | $5,400.00 | New | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Simmons Jeffrey N52 | President, CEO And Director | Buy | 22,000 | $24.00 | $528,000.00 | New | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Hoover R David50 | Director | Buy | 10,000 | $24.00 | $240,000.00 | New | |
| Sep 24, 2018 | AMRN Amarin Corp Plc\uk | Zakrzewski Joseph S55 | Director | Sell | 500,000 | $10.60 | $5,299,333.58 | -37.4% | |
| Sep 24, 2018 | ELAN Elanco Animal Health Inc | Kinard David S | See Remarks | Buy | 2,500 | $24.00 | $60,000.00 | New | |
| Sep 24, 2018 | PCRX Pacira Biosciences, Inc. | Riker Lauren Bullaro76 | Vice President, Finance | Sell | 1,000 | $50.70 | $50,700.00 | -8.7% |
The blue line has two modes, toggled with the Relative and Absolute buttons:
Relative (default) shows cumulative industry performance with both the overall market and parent sector movements removed. When the line rises above 100, the industry is outperforming its sector; below 100 means underperforming. This is calculated using factor returns via weighted least squares (WLS) regression, isolating pure industry-specific behavior.
Absolute shows the total cumulative return of the industry including market and sector movement. This reflects what an investor actually experienced — an industry can show strong absolute gains even while underperforming its sector in relative terms.
Both views start at an index of 100. Other return drivers such as momentum, value, or size are deliberately retained in both modes, since these are part of what makes an industry behave the way it does and may reflect the conditions insiders are responding to.